Recombinant Human TRANCE/RANK L/TNFSF11 Protein
Recombinant Human TRANCE/RANK L/TNFSF11 Protein Summary
Product Specifications
| MHHHHHHHHHH | GGGSGGGSGGGS | IEGR | Human TRANCE (Gly64-Asp245) Accession # AAC51762 |
| N-terminus | C-terminus | ||
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
390-TN
| Formulation | Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
390-TN/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in MOPS and NaCl. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant human TRANCE / RANK L / TNFSF11 (390-TN) induces osteoclast differentiation of the RAW264.7 mouse monocyte/macrophage cell line. The ED50 for this effect is 1.5-7.5 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine.
Reconstitution Calculator
Background: TRANCE/TNFSF11/RANK L
RANK Ligand (receptor activator of NF-kappa B ligand [RANKL], also called TNF-related activation-induced cytokines (TRANCE), osteoprotegerin ligand [OPGL], and osteoclast differentiation factor [ODF]), is a member of the tumor necrosis factor (TNF) family. RANK Ligand was originally identified as an immediate early gene up‑regulated by T cell receptor stimulation. The human RANK Ligand cDNA encodes a type II transmembrane protein of 317 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 249 amino acids. The extracellular domain contains two potential N‑linked glycosylation sites. Mouse and human RANK Ligand share 85% amino acid identity. RANK Ligand is primarily expressed in T cells and T cell rich organs, such as thymus and lymph nodes. The multi-functions of RANK Ligand include induction of activation of the c-jun N‑terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis, and lymph node organogenesis. RANK is the cell surface signaling receptor of RANK Ligand. RANK has been shown to undergo receptor clustering during signal transduction. Osteoprotegerin, a soluble member of the TNF receptor family which binds RANK Ligand, is a naturally occurring decoy receptor that counterbalances the effects of RANK Ligand.
- Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190.
- Anderson, D.M. et al. (1997) Nature 390:175.
- Nakagawa, N. et al. (1998) Biochem. Biophys. Res. Commun. 245:382.
- Kong, Y-Y. et al. (1999) Nature 397:315.
Citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
41
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Preosteoclast plays a pathogenic role in syndesmophyte formation of ankylosing spondylitis through the secreted PDGFB - GRB2/ERK/RUNX2 pathway
Authors: Tang, Y;Yang, K;Liu, Q;Ma, Y;Zhu, H;Tang, K;Geng, C;Xie, J;Zhuo, D;Wu, W;Jin, L;Xiao, W;Wang, J;Zhu, Q;Liu, J;
Arthritis research & therapy
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Refining Evaluation of Bone Mass and Adipose Distribution in Dunnigan Syndrome
Authors: Moreira, MLM;de Araújo, IM;Fukada, SY;Venturini, LGR;Guidorizzi, NR;Garrido, CE;Rosen, CJ;de Paula, FJA;
International journal of molecular sciences
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model
Authors: J Pape, D Bakkalci, RA Hosni, BS Simpson, K Heikinheim, S Fedele, U Cheema
Journal of tissue engineering, 2022-12-24;13(0):2041731422114.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption
Authors: D Ding, L Wang, J Yan, Y Zhou, G Feng, L Ma, Y Yang, X Pei, Q Jin
PLoS ONE, 2022-07-28;17(7):e0271485.
Species: Rat
Sample Types: Whole Cells
Applications: Bioassay -
Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-kappaB/ERK signaling pathway
Authors: H Guo, D Ding, L Wang, J Yan, L Ma, Q Jin
PLoS ONE, 2021-12-16;16(12):e0261127.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK
Authors: J Xue, L Xu, H Zhu, M Bai, X Li, Z Zhao, H Zhong, G Cheng, X Li, F Hu, Y Su
Arthritis Research & Therapy, 2020-09-21;22(1):221.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Environmental arginine controls multinuclear giant cell metabolism and formation
Authors: JS Brunner, L Vulliard, M Hofmann, M Kieler, A Lercher, A Vogel, M Russier, JB Brüggenthi, M Kerndl, V Saferding, B Niederreit, A Junza, A Frauenstei, C Scholtysek, Y Mikami, K Klavins, G Krönke, A Bergthaler, JJ O'Shea, T Weichhart, F Meissner, JS Smolen, P Cheng, O Yanes, J Menche, PJ Murray, O Sharif, S Blüml, G Schabbauer
Nat Commun, 2020-01-22;11(1):431.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis
Authors: KA Lee, KW Kim, BM Kim, JY Won, HK Min, DW Lee, HR Kim, SH Lee
Arthritis Res. Ther., 2019-12-12;21(1):283.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
Authors: I Zoi, MV Karamouzis, E Xingi, P Sarantis, D Thomaidou, P Lembessis, S Theocharis, AG Papavassil
Breast Cancer Res., 2019-12-03;21(1):132.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation
Authors: K Li, S Chen, P Cai, K Chen, L Li, X Yang, J Yi, X Luo, Y Du, H Zheng
Mol. Cell. Probes, 2019-11-06;0(0):101479.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps
Authors: N Ogasawara, JA Poposki, AI Klingler, BK Tan, KE Hulse, WW Stevens, AT Peters, LC Grammer, KC Welch, SS Smith, DB Conley, JR Raviv, P Soroosh, KI Takano, T Himi, RC Kern, RP Schleimer, A Kato
Mucosal Immunol, 2019-10-22;13(1):86-95.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential
Authors: IJ Yeh, SC Chen, MC Yen, YH Wu, CH Hung, PL Kuo
Nutrients, 2019-09-28;11(10):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels
Authors: FL Collins, MD Stone, J Turton, LR McCabe, ECY Wang, AS Williams
BMC Musculoskelet Disord, 2019-07-12;20(1):326.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro
Authors: H Löfvall, A Katri, A D?browska, MA Karsdal, Y Luo, Y He, T Manon-Jens, MH Dziegiel, AC Bay-Jensen, CS Thudium, K Henriksen
Sci Rep, 2019-02-28;9(1):3050.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Septins are critical regulators of osteoclastic bone resorption
Authors: AMJ Møller, EM Füchtbauer, A Brüel, TL Andersen, XG Borggaard, NJ Pavlos, JS Thomsen, FS Pedersen, JM Delaisse, K Søe
Sci Rep, 2018-08-29;8(1):13016.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis
Authors: CF Kjelgaard-, A Platt, M Braddock, MA Jenkins, K Musa, E Graham, T Gantzel, G Slynn, ME Weinblatt, MA Karsdal, CS Thudium, AC Bay-Jensen
Arthritis & rheumatology (Hoboken, N.J.), 2018-07-24;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain
Authors: C Davenport, E Harper, KD Rochfort, H Forde, D Smith, PM Cummins
J. Vasc. Res., 2018-04-10;55(2):111-123.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease
Authors: AW Clarke, L Poulton, D Shim, D Mabon, D Butt, M Pollard, V Pande, J Husten, J Lyons, C Tian, AG Doyle
MAbs, 2018-03-05;0(0):1-43.
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance (SPR -
Cathepsin K Localizes to Equine Boneand Inhibits Bone Marrow Stem and Progenitor Cells Differentiation
Authors: H Hussein, P Boyaka, J Dulin, D Russell, L Smanik, M Azab, AL Bertone
J Stem Cells Regen Med, 2017-12-18;13(2):45-53.
Species: Equine
Sample Types: Whole Cells
Applications: Bioassay -
Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells
Authors: A Sucur, Z Jajic, M Artukovic, MI Matijasevi, B Anic, D Flegar, A Markotic, T Kelava, S Ivcevic, N Kovacic, V Katavic, D Grcevic
Arthritis Res. Ther., 2017-06-15;19(1):142.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis
Authors: B Lu, Y Jiao, Y Wang, J Dong, M Wei, B Cui, Y Sun, L Wang, B Zhang, Z Chen, Y Zhao
Exp. Mol. Med., 2017-05-19;49(5):e336.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity
Authors: G Chinetti-G, M Daoudi, M Rosa, M Vinod, L Louvet, C Copin, M Fanchon, J Vanhoutte, B Derudas, L Belloy, S Haulon, C Zawadzki, S Susen, ZA Massy, J Eeckhoute, B Staels
Circ. Res., 2017-04-24;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan
Authors: A Kamalakar, CL Washam, NS Akel, BJ Allen, DK Williams, FL Swain, K Leitzel, A Lipton, D Gaddy, LJ Suva
J. Bone Miner. Res., 2017-04-19;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
PKC?II-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity
Authors: Giulia Bellini
Pharmacol. Res, 2016-12-02;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis
Authors: Justin R Savage
PLoS ONE, 2016-06-16;11(6):e0157310.
Applications: Bioassay -
Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro.
Authors: Kasonga A, Deepak V, Kruger M, Coetzee M
PLoS ONE, 2015-04-13;10(4):e0125145.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy.
Authors: Zhu K, Yi J, Xiao Y, Lai Y, Song P, Zheng W, Jiao H, Fan J, Wu C, Chen D, Zhou J, Xiao G
J Biol Chem, 2015-02-03;290(13):8081-94.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-kappaB pathway in osteoclasts.
Authors: Kalbasi Anaraki P, Patecki M, Tkachuk S, Kiyan Y, Haller H, Dumler I
J Bone Miner Res, 2015-02-01;30(2):379-88.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis.
Authors: Alshbool F, Mohan S
PLoS ONE, 2014-12-05;9(12):e114357.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Authors: Zheng Y, Chow S, Boernert K, Basel D, Mikuscheva A, Kim S, Fong-Yee C, Trivedi T, Buttgereit F, Sutherland R, Dunstan C, Zhou H, Seibel M
J Bone Miner Res, 2014-09-01;29(9):1938-49.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLCgamma-independent Ca2+ oscillation.
Authors: Yeon J, Kim K, Choi S, Moon S, Park Y, Ryu B, Oh J, Kim M, Erkhembaatar M, Son Y, Kim S
PLoS ONE, 2014-02-21;9(2):e88974.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
MiR-503 regulates osteoclastogenesis via targeting RANK.
Authors: Chen C, Cheng P, Xie H, Zhou H, Wu X, Liao E, Luo X
J Bone Miner Res, 2014-02-01;29(2):338-47.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
Authors: Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak L, Yi Q, Yang J
PLoS ONE, 2013-12-10;8(12):e82453.
Species: Human
Sample Types:
Applications: Bioassay -
Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.
Authors: He W, Mazumder A, Wilder T, Cronstein B
FASEB J, 2013-05-16;27(9):3446-54.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
Nature, 2012-07-26;487(7408):505-9.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle.
Authors: Soe K, Delaisse JM
J. Bone Miner. Res., 2010-10-01;25(10):2184-92.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Authors: Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM
Leuk. Res., 2008-04-18;32(11):1661-8.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
Authors: Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Quarta L, Cirulli N, Mancini L, Corrado A, Grassi FR, Grano M
J. Pathol., 2007-05-01;212(1):47-55.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.
Authors: Tang CH, Hsu TL, Lin WW, Lai MZ, Yang RS, Hsieh SL, Fu WM
J. Biol. Chem., 2006-11-10;282(4):2346-54.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease.
Authors: Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, Goncalves RB, Valverde P, Dibart S, Li YP, Miranda LA, Ernst CW, Izumi Y, Taubman MA
Am. J. Pathol., 2006-09-01;169(3):987-98.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Authors: Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
Am. J. Pathol., 2003-11-01;163(5):2021-31.
Applications: ELISA (Standard)
FAQs
-
This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?
The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.
-
Is this protein provided in trimeric form or monomer form?
We do not define this protein as being exclusively a monomer, but we know that the protein is not fully associated into trimers because we need to use a cross-linking antibody for our in-house activity testing to cause multiple subunits of this protein to associate. This product has been shown to be biologically active in such testing when a cross-linking antibody is used. Therefore, we would expect for this protein to perform its expected biological function.
-
What are the differences between the Recombinant Human TRANCE/RANK L/TNFSF11 Protein (Catalog # 390-TN) and the Recombinant Human TRANCE/RANK L/TNFSF11 (Catalog # 6449-TEC)?
6449-TEC is the truncated version of 390-TN, and it contains a 10-His tag in the N-terminus. The bioactivity of 390-TN and 6449-TEC are measured in the same assay described in the datasheet, "Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells." However, 390-TN utilizes a cross-linking antibody, MAB050, as it requires receptor trimerization which results in higher bioactivity. The ED50 for 390-TN is 1.5-7.5 ng/mL in the presence of MAB050, while the ED50 for 6449-TEC is 2-12 ng/mL.
Reviews for Recombinant Human TRANCE/RANK L/TNFSF11 Protein
Average Rating: 4.8 (Based on 8 Reviews)
Have you used Recombinant Human TRANCE/RANK L/TNFSF11 Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: Steady quality! 60 ng/ml RANKL can induce monocyte to osteoclast very well.
Reason for Rating: 50ng/ml RANKL is good for induce the human monocyte to osteoclast.
Reason for Rating: 50ng/ml RANKL, 25ng/ml M-CSF in a-MEM works well for human osteoclasts.
